Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujiro Sato

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Molecular and Clinical Oncology|February 2, 2018
Effect of dutasteride on castration-resistant prostate cancerTakeshi Azuma, Yukihide Matayoshi, Yujiro Sato, et al.
Plos One|July 26, 2018
Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinomaTakeshi Azuma, Yujiro Sato, Tetsukuni Ohno, et al.
Case Reports in Urology|September 13, 2012
Metastatic renal cell carcinoma change vascularityTakeshi Azuma, Yukihide Matayoshi, Yohsuke Sato, et al.
Plos One|December 11, 2020
Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancerTakeshi Azuma, Yujiro Sato, Tatsukuni Ohno, et al.
Japanese Journal of Clinical Oncology|July 20, 2016
The safety and effect of chemotherapy with short hydration for urothelial cancer on patients' quality of lifeTakeshi Azuma, Yukihide Matayoshi, Yujiro Sato, et al.
Japanese Journal of Clinical Oncology|April 24, 2018
Drug review: PazopanibShingo Miyamoto, Shigenori Kakutani, Yujiro Sato, et al.
Clinical Genitourinary Cancer|May 14, 2013
Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinomaTakeshi Azuma, Yukihide Matayoshi, Keiko Odani, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|January 31, 2017
METASTATIC SMALL CELL CARCINOMA OF THE URINARY BLADDER TREATED WITH SYSTEMIC CHEMOTHERAPY INCLUDING AN AMRUBICIN; A CASE REPORTAkihiro Naito, Akihiko Matsumoto, Keiko Odani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Molecular and Clinical Oncology|February 2, 2018
Effect of dutasteride on castration-resistant prostate cancerTakeshi Azuma, Yukihide Matayoshi, Yujiro Sato, et al.
Plos One|July 26, 2018
Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinomaTakeshi Azuma, Yujiro Sato, Tetsukuni Ohno, et al.
Case Reports in Urology|September 13, 2012
Metastatic renal cell carcinoma change vascularityTakeshi Azuma, Yukihide Matayoshi, Yohsuke Sato, et al.
Plos One|December 11, 2020
Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancerTakeshi Azuma, Yujiro Sato, Tatsukuni Ohno, et al.
Japanese Journal of Clinical Oncology|July 20, 2016
The safety and effect of chemotherapy with short hydration for urothelial cancer on patients' quality of lifeTakeshi Azuma, Yukihide Matayoshi, Yujiro Sato, et al.
Japanese Journal of Clinical Oncology|April 24, 2018
Drug review: PazopanibShingo Miyamoto, Shigenori Kakutani, Yujiro Sato, et al.
Clinical Genitourinary Cancer|May 14, 2013
Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinomaTakeshi Azuma, Yukihide Matayoshi, Keiko Odani, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|January 31, 2017
METASTATIC SMALL CELL CARCINOMA OF THE URINARY BLADDER TREATED WITH SYSTEMIC CHEMOTHERAPY INCLUDING AN AMRUBICIN; A CASE REPORTAkihiro Naito, Akihiko Matsumoto, Keiko Odani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 1